| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514196000 | 6-position substituent contains hetero ring | 18 |
| 20090111788 | ANTIBIOTIC COMPOSITIONS OF MODIFIED RELEASE AND PROCESS OF PRODUCTION THEREOF - Novel modified release pharmaceutical compositions wherein the composition comprises at least one antibiotic(s) preferably amoxicillin or its pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof either alone or in combination with other antibiotic(s) as active ingredient, with at least one release modifying agent(s) for controlling the release of the beta lactam antibiotic optionally with one or more other pharmaceutically acceptable excipient(s) is provided, wherein the dosage form provides a release of not more than about 60% of the antibiotic in about 30 minutes and not less than about 70% of the antibiotic after 8 hours when subjected to in vitro dissolution study or when tested in vivo. Further, the compositions of the present invention which when tested in a group of healthy humans provide a mean peak plasma concentration (C | 04-30-2009 |
| 20100029604 | ANTIBACTERIAL COMBINATION AND ITS USE - The invention relates to a pharmaceutical composition comprising an ethylene derivatives of tricyclic carbapenems of the general Formula (I) in the form of pure diastereoisomers and in the form of pure geometric isomers or a salt, ester or amide derivate thereof and an antibiotic and the use of this composition as a broad band spectrum β-lactamase inhibitor. | 02-04-2010 |
| 20100105649 | VETERINARY COMPOSITIONS FOR TREATING MASTITIS - The present invention relates to a veterinary composition for the prophylaxis and treatment of mastitis in mammals, preferably cows. The formulations of the present invention comprise two parts that are optionally administered to the animal as a blended formulation or two separate formulations. The first part is a seal formulation comprising a gel base and a non-toxic heavy metal salt in the base. The second part of the formulation is an oil-based product preferably containing an antibiotic in an oil-based formulation. The oil-based formulation may also optionally contain any other pharmaceutically active agent for the treatment or prophylaxis of disease in cattle. | 04-29-2010 |
| 20110046101 | BATE-LACTAMASE INHIBITORS - The present invention relates to broad spectrum β-lactamase inhibitors. More particularly, the invention relates to inhibitors of Class B metallo (MBL) and Class D (OXA) β-lactamases. A method of treating a bacterial infection is provided, wherein the method comprises administering to a mammalian patient in need of such treatment a compound of formula (I) | 02-24-2011 |
| 20110086831 | PROCALCITONIN FOR THE DIAGNOSIS OF BACTERIAL INFECTIONS AND GUIDANCE OF ANTIBIOTIC TREATMENT IN PATIENTS WITH ACUTE STROKE OR TRANSIENT ISCHEMIC ATTACK - The present invention relates to an in vitro method for the diagnosis and treatment guidance of a bacterial infection in patients suffering from an acute ischemic or hemorrhagic stroke, comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from said patient and the correlation of the determined level to the diagnosis of a bacterial infection in said patient. | 04-14-2011 |
| 20110152231 | METHYLSULFONYLMETHANE (MSM) FOR TREATMENT OF DRUG RESISTANT MICROORGANISMS - Embodiments of the invention relate generally to the use of compositions comprising methylsulfonylmethane (MSM), and one or more therapeutic agents, for the treatment of drug-sensitive and drug resistant microorganisms. In several embodiments, such compositions are effective in treating drug resistant infectious diseases, for example, MRSA. | 06-23-2011 |
| 20110294774 | IDENTIFICATION AND APPLICATION OF ANTIBIOTIC SYNERGY - The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a β-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC, MurD, MurE, MurF, MurG, MraY, and UppS. Further provided is a method of discovering synergists for antibiotics including: a) expressing in a cell an antisense nucleic acid against a nucleic acid encoding a gene product so as to reduce the activity or amount of the gene product in the cell, thereby producing a cell sensitized to an antibiotic; b) characterizing the sensitization of the cell to the antibiotic and selecting pairs of antibiotics and genes that result in antibiotic efficacy at one-fifth or less the concentration required in the absence of the antisense gene; c) screening for chemical compounds that inhibit the gene product corresponding to the selected synergistic gene; and d) selecting or creating chemical analogs that inhibit the gene product corresponding to the selected synergistic gene such that the inhibition occurs in the bacteria. | 12-01-2011 |
| 20120122831 | METHOD AND DEVICE FOR RAPID DETECTION OF BACTERIAL ANTIBIOTIC RESISTANCE/SUSCEPTIBILITY - Described herein is a method and a device for expediting delivery of an agent to a damaged bacterial cell. In one embodiment, the methods and devices are useful for screening candidate antibiotics. In another embodiment, the methods and devices described herein are used to determine susceptibility of bacteria to an antibiotic. The methods also provide a method for determining an appropriate antibiotic to treat an individual having a bacterial infection. | 05-17-2012 |
| 20120149672 | METHYLSULFONYLMETHANE (MSM) FOR TREATMENT OF DRUG RESISTANT MICROORGANISMS - Embodiments of the invention relate generally to the use of compositions comprising methylsulfonylmethane (MSM), and one or more therapeutic agents, for the treatment of drug-sensitive and drug resistant microorganisms. In several embodiments, such compositions are effective in treating drug resistant infectious diseases, for example, MRSA. | 06-14-2012 |
| 20130018029 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS - The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate. | 01-17-2013 |
| 20130065874 | METHODS FOR TREATING INTRAPULMONARY INFECTIONS - This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane. | 03-14-2013 |
| 20130143856 | NOVEL ANTIBIOTIC COMPOSITION COMPRISING FLUFENAMIC ACID AS AN ACTIVE INGREDIENT - The present invention relates to a novel antibiotic, and more specifically relates to an antibiotic composition comprising flufenamic acid as an active ingredient, which can reduce drug toxicity and side effects and the problem of antibiotic resistance caused by excessive use of antibiotics since the composition exhibits a good therapeutic effect, even in a small dose, when it is administered either alone or together with another antibiotic of the prior art. | 06-06-2013 |
| 20130338130 | METHYLSULFONYLMETHANE (MSM) FOR TREATMENT OF DRUG RESISTANT MICROORGANISMS - Embodiments of the invention relate generally to the use of compositions comprising methylsulfonylmethane (MSM), and one or more therapeutic agents, for the treatment of drug-sensitive and drug resistant microorganisms. In several embodiments, such compositions are effective in treating drug resistant infectious diseases, for example, MRSA. | 12-19-2013 |
| 20140088069 | NOVEL ANTIBACTERIAL COMBINATION THERAPY - An antibacterial composition is provided including a combination of a β-lactam antibiotic that has a binding affinity for bacterial penicillin-binding protein 2; and a non-antibiotic compound which may be a thienopyridine or a non-thienopyridine compound. A method of treatment using the composition is also provided. | 03-27-2014 |
| 20140107092 | BACTERIAL ETIOLOGY OF COLORECTAL CANCER - Methods for predicting risk of developing colorectal cancer, for treating colorectal cancer, and reducing risk of developing colorectal cancer. | 04-17-2014 |
| 20150045337 | CONTROLLED RELEASE COMPOSITIONS AND THEIR METHODS OF USE - The present invention relates to a composition, the composition including a therapeutically effective amount of at least one active agent, and a base including, an amount of colloidal silica; at least one oil; and at least one surfactant, wherein the viscosity of the composition is below 1000 mPas at a shear rate of 100 l/s and at a temperature of 20° C. | 02-12-2015 |
| 20150299222 | COCRYSTAL OF PIPERACILLIN SODIUM AND SULBACTAM SODIUM AND PREPARATION METHOD THEREOF, AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF - Provided in the present invention are a cocrystal of piperacillin sodium and sulbactam sodium and preparation method thereof, as well as pharmaceutical compositions containing the same and uses thereof in treating infections caused by drug-resistant bacteria, such as a “super bacterium” producing NDM-1 and the like. The cocrystal of piperacillin sodium and sulbactam sodium contains diffraction angles of 14.24°, 16.58°, 16.79°, 17.77°, 19.20°, 20.21°, 20.39°, 23.06°, 27.86° and 32.16° represented by 2θ in an X-ray powder diffraction analysis spectrum. | 10-22-2015 |
| 20160175290 | BETA-LACTAMASE INHIBITOR COMPOUNDS | 06-23-2016 |
